Compare Symbotic Inc (SYM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Symbotic Inc vs Viatris Inc — how do they compare? Symbotic Inc trades at $42.89 (market cap $5.62B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is far larger — about 3.4× Symbotic Inc's market cap, and Viatris Inc pays a 2.89% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| SYM | VTRS | |
|---|---|---|
Market Cap | $5.62B | $19.09B |
Sector | Technology | Health |
52-Week High | $87.30 | $17.86 |
52-Week Low | $38.22 | $9.49 |
Enterprise Value | $3.88B | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYM trades at $43.30, up 0.84% today, with a bullish technical signal from moving averages and ADX indicators. The company reported revenue of $2.25B in 2025 but posted a net loss of $16.94M, though 2026 projections show potential profitability. Analyst consensus is bullish with a $56.50 price target, representing 30% upside potential from current levels. Recent news highlights Symbotic's $22.5B backlog and strategic partnership with Stanford Robotics Center.
SYM presents growth potential with strong revenue projections and massive backlog, but faces risks from customer concentration (85% revenue from Walmart) and recent earnings misses. The stock appears undervalued with a P/E of 1,082.5, though negative EBITDA and thin margins warrant caution. Institutional interest remains positive with new investments, but insider selling and legal investigations create near-term headwinds.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
